Skip to main content
Dr. Jack Cush reviews autoantibody testing in rheumatology.
AANP survey of US 2338 Nurse Practitioners (mostly primary care) re: shared pts w/ rheumatologists. NPs managing RA want

Dr. John Cush RheumNow

7 months 2 weeks ago
AANP survey of US 2338 Nurse Practitioners (mostly primary care) re: shared pts w/ rheumatologists. NPs managing RA want improved communication w/ rheums, & education on RA management. PC NP confidence w/ RA was 47% Somewhat confident, 6% very confident, 19% not confident. https://t.co/YVEpJua9hj
Top 10 States to Practice Rheumatology
1 North Dakota
2 Wisconsin
3 Alaska
4 Montana
5 South Dakota
6 Nebraska
7 Minne

Dr. John Cush RheumNow

7 months 2 weeks ago
Top 10 States to Practice Rheumatology 1 North Dakota 2 Wisconsin 3 Alaska 4 Montana 5 South Dakota 6 Nebraska 7 Minnesota 8 Washington 9 Utah 10 Maine https://t.co/x2tKflV2S7 https://t.co/fLMEhQV0js
Tarsal Tunnel Syndrome - review and quiz.
A compressive neuropathy of the posterior tibial nerve within the tarsal tunne

Dr. John Cush RheumNow

7 months 2 weeks ago
Tarsal Tunnel Syndrome - review and quiz. A compressive neuropathy of the posterior tibial nerve within the tarsal tunnel. 80% caused by lipoma, ganglion, varicosity, trauma, tenosynovitis, rheumatoid arthritis, diabetes, etc https://t.co/zCyeVIJEuy https://t.co/f4jA13FDvN
In US, Tofacitinib loses patent exclusivity & goes generic in 2026. Worldwide Tofa sales in 2024 were $3.08 billio

Dr. John Cush RheumNow

7 months 2 weeks ago
In US, Tofacitinib loses patent exclusivity & goes generic in 2026. Worldwide Tofa sales in 2024 were $3.08 billion (55% use in RA; N. America 1st w/ ~38% of market). Tofa sales projected to rise to $5.7 bill in 2029 https://t.co/nKPaQdglYw https://t.co/DdMymmk8go
A large observational cohort study suggests that monitoring hydroxychloroquine (HCQ) blood levels is effective in systemic lupus erythematosus (SLE) patients with a target therapeutic range (for HCQ level monitoring) of 750-1150 ng/ml.
Israeli retrospective study of 9736 colchicine Rx FMF pts matched w/ 97 360 controls. On F/U Psoriatic arthritis develo

Dr. John Cush RheumNow

7 months 2 weeks ago
Israeli retrospective study of 9736 colchicine Rx FMF pts matched w/ 97 360 controls. On F/U Psoriatic arthritis developed in more FMF pts (43 vs 119) - HR 3.52 (CI: 2.48, 5.0). ^Risk w/ older age, smoking, SES https://t.co/blDIsmHWPC
Survey of physician assistants finds 56% use AI daily (19% AI extensively). 87% PAs say they need to learn more about AI

Dr. John Cush RheumNow

7 months 2 weeks ago
Survey of physician assistants finds 56% use AI daily (19% AI extensively). 87% PAs say they need to learn more about AI, 83% desire formal, employer-led AI training. 89% believe AI will dramatically changes PA practice, but only 32% have clear workplace guidelines on AI usage https://t.co/yGqZRC3mNt
2025 Adult Rheumatology Fellowship Match is Strong (Again)

The ACR announced today that 2025 Medicine and Pediatric Sp

Dr. John Cush RheumNow

7 months 2 weeks ago
2025 Adult Rheumatology Fellowship Match is Strong (Again) The ACR announced today that 2025 Medicine and Pediatric Specialties Match results show rheumatology fellowship positions continuing to fill at high rates. The Match uses a computerized process to pair applicant and https://t.co/1p7o10kLPR
In orthopedic practice, missing the wrong fracture can significantly alter a patient’s outcome. Certain injuries may appear subtle on initial imaging yet carry serious consequences if not promptly recognized and managed. Below are five fractures that warrant a high index of suspicion due to their risk of displacement, nonunion, or long‑term degenerative change.
I Can't Believe it's Not Seronegative Rheumatoid Arthritis?!

In rheumatology, we're no stranger to uncertainty. In any

Dr. John Cush RheumNow

7 months 2 weeks ago
I Can't Believe it's Not Seronegative Rheumatoid Arthritis?! In rheumatology, we're no stranger to uncertainty. In any diagnosis of seronegative rheumatoid arthritis, it's always our invitation to reconsider the diagnosis. https://t.co/JaLfRha6dq https://t.co/WwT5Q8B5Ad
APP QD Clinic: Difficult AxSpA

Philip Mease, MD and Christy Vath, PA-C, Seattle discuss a difficult to treat axial spo

Dr. John Cush RheumNow

7 months 2 weeks ago
APP QD Clinic: Difficult AxSpA Philip Mease, MD and Christy Vath, PA-C, Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/VY0O26l7XC
Dr, Tuhina Neogi writes its time for a new understanding of OA; its not just wear n tear. Based on preclinical and clini

Dr. John Cush RheumNow

7 months 2 weeks ago
Dr, Tuhina Neogi writes its time for a new understanding of OA; its not just wear n tear. Based on preclinical and clinical evidence, OA is a systemic, whole-body disease and that this should change future research and treatment of #OA. https://t.co/gn9xt6CafP https://t.co/2iSKiyiCX4
British Society of Rheumatology Guideline for Monitoring DMARDs

The British Society of Rheumatology has published an u

Dr. John Cush RheumNow

7 months 2 weeks ago
British Society of Rheumatology Guideline for Monitoring DMARDs The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic https://t.co/iANvir1EFI
×